SMT201800143T1 - Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico - Google Patents

Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico

Info

Publication number
SMT201800143T1
SMT201800143T1 SM20180143T SMT201800143T SMT201800143T1 SM T201800143 T1 SMT201800143 T1 SM T201800143T1 SM 20180143 T SM20180143 T SM 20180143T SM T201800143 T SMT201800143 T SM T201800143T SM T201800143 T1 SMT201800143 T1 SM T201800143T1
Authority
SM
San Marino
Prior art keywords
coagulative
glycosaminoglycans
medical use
disaccharide unit
repeating disaccharide
Prior art date
Application number
SM20180143T
Other languages
English (en)
Italian (it)
Inventor
Hans-Peter Ekre
Per-Olov Eriksson
Ulf Lindahl
Erik Holmer
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201800143(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of SMT201800143T1 publication Critical patent/SMT201800143T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SM20180143T 2011-12-19 2012-12-19 Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico SMT201800143T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
EP12858809.2A EP2794665B1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Publications (1)

Publication Number Publication Date
SMT201800143T1 true SMT201800143T1 (it) 2018-05-02

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20180143T SMT201800143T1 (it) 2011-12-19 2012-12-19 Glicosaminoglicani non anticoagulanti comprendenti un'unita ripetitiva di disaccaridi e loro uso medico

Country Status (28)

Country Link
US (1) US9475888B2 (cg-RX-API-DMAC7.html)
EP (1) EP2794665B1 (cg-RX-API-DMAC7.html)
JP (2) JP6543467B2 (cg-RX-API-DMAC7.html)
KR (1) KR102135485B1 (cg-RX-API-DMAC7.html)
CN (1) CN104144950B (cg-RX-API-DMAC7.html)
AU (1) AU2012354229B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014014454B1 (cg-RX-API-DMAC7.html)
CA (1) CA2856492C (cg-RX-API-DMAC7.html)
CL (1) CL2014001651A1 (cg-RX-API-DMAC7.html)
CO (1) CO7061069A2 (cg-RX-API-DMAC7.html)
CY (1) CY1119899T1 (cg-RX-API-DMAC7.html)
DK (1) DK2794665T3 (cg-RX-API-DMAC7.html)
ES (1) ES2656613T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180124T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036523T2 (cg-RX-API-DMAC7.html)
IL (1) IL232905A (cg-RX-API-DMAC7.html)
LT (1) LT2794665T (cg-RX-API-DMAC7.html)
ME (1) ME02994B (cg-RX-API-DMAC7.html)
MX (1) MX351104B (cg-RX-API-DMAC7.html)
NO (1) NO2904345T3 (cg-RX-API-DMAC7.html)
PL (1) PL2794665T3 (cg-RX-API-DMAC7.html)
PT (1) PT2794665T (cg-RX-API-DMAC7.html)
RS (1) RS56874B1 (cg-RX-API-DMAC7.html)
RU (1) RU2617764C2 (cg-RX-API-DMAC7.html)
SI (1) SI2794665T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800143T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013095279A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403640B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CA2868444A1 (en) * 2012-03-26 2013-10-03 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
CA2868479A1 (en) * 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
MX2014013449A (es) * 2012-05-08 2014-12-08 Dilafor Ab Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico.
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
CN107001488B (zh) * 2014-04-30 2020-05-12 新加坡科技研究局 硫酸乙酰肝素
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
EP4106765A1 (en) 2020-02-17 2022-12-28 Dilafor AB Tafoxiparin for the treatment of preeclampsia
JP2025514038A (ja) 2022-05-03 2025-05-02 ディラフォール アクチエボラグ タフォキシパリンの新規な医学的使用
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
ATE224918T1 (de) * 1995-03-31 2002-10-15 Hamilton Civic Hospitals Res Zusammensetzung zur hemmung der thromboseentstehung
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998016559A1 (fr) 1996-10-15 1998-04-23 Toray Industries, Inc. Agent de maturation des canaux cervicaux
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
EP1033375A4 (en) * 1997-11-20 2002-04-24 Ikuo Yamashina MODIFICATION OF LOW MOLECULAR MASS HEPARIN AND REMEDY FOR SKIN Ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
EP1059304B1 (en) 1998-02-26 2006-04-26 Seikagaku Corporation Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
EP1022289B1 (en) * 1998-07-31 2004-07-07 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
WO2000013019A1 (en) * 1998-08-26 2000-03-09 The Collaborative Group, Ltd. Receptor for underivatized, aqueous soluble beta-(1,3)-glucan
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
DK1319183T3 (da) * 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2003088980A1 (en) 2002-04-18 2003-10-30 Embury Stephen H Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
EP1906975A4 (en) 2005-07-22 2010-10-06 Trf Pharma Inc METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
EP1906974A4 (en) * 2005-07-22 2010-06-23 Univ California HEPARINE COMPOSITIONS AND SELECTIN INHIBITION
EP2386858B1 (en) * 2006-04-04 2015-07-15 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
MY151984A (en) * 2007-11-02 2014-07-31 Momenta Pharmaceuticals Inc Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
WO2010111570A1 (en) * 2009-03-27 2010-09-30 E. I. Du Pont De Nemours And Company Polyglycerol aldehydes
CA2758520A1 (en) 2009-04-16 2010-10-21 Momenta Pharmaceuticals, Inc. Methods of assessing activity of a polysaccharide composition
WO2011000032A1 (en) 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
KR20120060209A (ko) * 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ix 폴리펩티드 및 그의 용도
ES2551388T3 (es) * 2009-12-22 2015-11-18 Lifebond Ltd Modificación de agentes de entrecruzamiento enzimáticos para controlar las propiedades de las matrices entrecruzadas
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CA2868479A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Method for treatment of labor arrest
CA2868444A1 (en) 2012-03-26 2013-10-03 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor

Also Published As

Publication number Publication date
KR20140113652A (ko) 2014-09-24
US9475888B2 (en) 2016-10-25
EP2794665B1 (en) 2017-11-22
HUE036523T2 (hu) 2018-07-30
CL2014001651A1 (es) 2014-10-10
RU2014129816A (ru) 2016-02-20
RU2617764C2 (ru) 2017-04-26
HRP20180124T1 (hr) 2018-02-23
EP2794665A1 (en) 2014-10-29
JP6543467B2 (ja) 2019-07-10
IL232905A0 (en) 2014-07-31
JP2018111825A (ja) 2018-07-19
IL232905A (en) 2017-02-28
ME02994B (me) 2018-10-20
MX351104B (es) 2017-10-02
CN104144950A (zh) 2014-11-12
RS56874B1 (sr) 2018-04-30
BR112014014454A2 (pt) 2017-06-13
EP2794665A4 (en) 2015-08-26
SI2794665T1 (en) 2018-03-30
LT2794665T (lt) 2017-12-27
MX2014007122A (es) 2015-03-05
JP2015500388A (ja) 2015-01-05
WO2013095279A1 (en) 2013-06-27
NO2904345T3 (cg-RX-API-DMAC7.html) 2018-07-21
ZA201403640B (en) 2017-06-28
ES2656613T3 (es) 2018-02-27
CY1119899T1 (el) 2018-06-27
CA2856492A1 (en) 2013-06-27
PT2794665T (pt) 2018-01-24
AU2012354229A1 (en) 2014-06-05
PL2794665T3 (pl) 2018-04-30
US20150011505A1 (en) 2015-01-08
HK1202883A1 (en) 2015-10-09
CO7061069A2 (es) 2014-09-19
KR102135485B1 (ko) 2020-07-17
BR112014014454B1 (pt) 2021-03-09
DK2794665T3 (da) 2018-01-29
CN104144950B (zh) 2017-09-05
AU2012354229B2 (en) 2016-12-01
CA2856492C (en) 2017-01-10

Similar Documents

Publication Publication Date Title
IL232905A (en) Non-coagulant glycosaminoglycans that include a repeat discharged unit and their medical use
EP2797512A4 (en) MEDICAL DEVICES FOR ASSESSING IMAGE SUPPORT AND PROCEDURE
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
PL2403854T3 (pl) Sulfonylowane tetrahydroazolopirazyny i ich zastosowanie jako produktów leczniczych
EP2563426A4 (en) APPLICATION WITH HIGH SCAM FOR MEDICAL THERAPY
GB201120345D0 (en) Medical console
GB201010193D0 (en) Medicinal use
ZA201404633B (en) Compositions comprising c5 and c6 oligosaccharides
ZA201208173B (en) Peptices and their use
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
EP2740728A4 (en) URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
IL228436A0 (en) Pyridopyrazine history and their use
ZA201405039B (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin
EP2730230A4 (en) ULTRASOUND UNIT AND ULTRASOUND ENDOSCOPE
IL232824A0 (en) Medical and/or diagnostic nanocarriers targeting mmp
IL232174A0 (en) Preparations containing a salt of a sodium channel inhibitor and their uses
PL2582733T3 (pl) Polimery z bocznymi grupami sacharydowymi i ich zastosowanie
IL232239A0 (en) Medical use
EP2893881A4 (en) ULTRASOUND UNIT AND ULTRASOUND ENDOSCOPE
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
SI2536400T1 (sl) Zdravilo, ki vsebuje miramistin
EP2859852A4 (en) ULTRASONIC UNIT AND ULTRASOUND DOSCOPE
GB201215502D0 (en) Medical use
ZA201304369B (en) Use of glycosaminoglycan lipote esters in the trichology field
GB201112578D0 (en) Pharmaceutical preparation and use